Normal Pressure Hydrocephalus

Comprehensive Clinical Guide: Normal Pressure Hydrocephalus (NPH)

1. Introduction and Clinical Overview

Normal Pressure Hydrocephalus (NPH) represents a unique and often reversible form of communicating hydrocephalus characterized by the clinical triad of gait disturbance, urinary incontinence, and cognitive decline (dementia). Unlike obstructive hydrocephalus, where intracranial pressure (ICP) is markedly elevated, NPH is defined by ventricular enlargement out of proportion to brain atrophy, occurring in the presence of normal or only transiently elevated cerebrospinal fluid (CSF) pressure on lumbar puncture.

Clinically, NPH is categorized into two primary forms:
* Idiopathic NPH (iNPH): Occurring primarily in the elderly population (typically >60 years) with no identifiable preceding cause.
* Secondary NPH (sNPH): Arising as a sequela of known neurological insults, such as subarachnoid hemorrhage (SAH), meningitis, or severe traumatic brain injury.

Recognizing NPH is of paramount clinical importance in orthopedic and neurological practice because it is one of the few "treatable" causes of dementia. Failure to diagnose NPH in a timely manner often leads to permanent neurological morbidity, particularly in gait stability, which significantly increases the risk of fractures and orthopedic complications in geriatric patients.

2. Pathophysiology and Mechanisms

The pathophysiology of NPH is multifactorial and remains a subject of intense investigation. The prevailing theory involves the "pulsatile flow" hypothesis, which suggests that altered CSF dynamics—specifically increased pulse pressure within the ventricles—lead to mechanical stress on the periventricular white matter.

Key Mechanisms:

The hallmark of the disease is the ventricular enlargement that occurs without a proportional increase in cortical sulcal atrophy. This is quantified by the Evans’ Index (the ratio of the maximum width of the frontal horns to the maximum internal diameter of the skull), where a value >0.3 is highly suggestive of NPH.

3. Clinical Presentation and Staging

The classic presentation is the "Hakim-Adams Triad." However, it is critical to note that the full triad is present in only about 50-60% of patients at the time of initial presentation.

The Hakim-Adams Triad:

1. Gait Disturbance (The "Magnetic Gait"): Often the first and most prominent symptom. Patients exhibit a wide-based, slow, shuffling gait. It is frequently described as "magnetic," as if the feet are stuck to the floor.
2. Urinary Incontinence: Usually appearing later in the disease course. It starts as urgency and frequency, progressing to frank incontinence.
3. Cognitive Decline: Characterized by executive dysfunction, psychomotor slowing, and apathy rather than the memory loss typically seen in Alzheimer’s disease.

Clinical Staging (The iNPH Grading Scale):

The iNPH scale evaluates the severity of the triad on a 0–12 point basis:
* Gait (0–4): From normal to unable to walk.
* Cognition (0–4): From normal to severe dementia.
* Urinary (0–4): From normal to total incontinence.

4. Differential Diagnosis

Distinguishing NPH from other neurodegenerative conditions is essential for surgical planning.

• Alzheimer’s Disease: Memory loss is the primary feature; gait is usually preserved until the late stages.
• Parkinson’s Disease: Characterized by resting tremor, rigidity, and bradykinesia. NPH patients lack the classic "pill-rolling" tremor and respond poorly to levodopa.
• Vascular Dementia: Typically features focal neurological deficits and clear evidence of cerebrovascular disease on imaging.
• Cervical Spondylotic Myelopathy: Can mimic the gait disturbance of NPH. In orthopedic clinical settings, it is vital to rule out cervical cord compression via MRI/CT if gait instability is the primary complaint.

5. Diagnostic Testing Protocols

Diagnostic confirmation relies on a combination of imaging and CSF drainage trials.

1. Structural Imaging (MRI/CT):
   • Ventricular enlargement (Evans’ Index > 0.3).
   • Narrowing of the sulci at the vertex (the "tight high-convexity" sign).
   • Evidence of periventricular T2/FLAIR hyperintensities (suggesting interstitial edema).
2. CSF Tap Test (Large Volume Lumbar Puncture):
   • Removal of 30–50 mL of CSF.
   • A positive response is defined by a significant improvement in gait (speed/stride length) within 24 hours.
3. Extended Lumbar Drainage (ELD):
   • If the tap test is equivocal, a lumbar drain is placed for 3–5 days to monitor sustained improvement.
4. Radionuclide Cisternography: Rarely used today, but historically employed to observe the flow of CSF into the ventricles (ventricular reflux).

6. Surgical Management: Risks and Prognosis

The definitive treatment for NPH is the surgical placement of a Ventriculoperitoneal (VP) Shunt.

Risks and Contraindications:

• Surgical Risks: Infection (meningitis/ventriculitis), intracranial hemorrhage, shunt obstruction, or over-drainage (leading to subdural hematomas).
• Contraindications: Patients with severe systemic comorbidities (e.g., end-stage heart failure) where the risks of anesthesia outweigh the potential benefits of the shunt.

Long-term Prognosis:

• Success Rates: Approximately 70-80% of patients show significant improvement post-shunt, particularly in gait.
• Cognitive Outcomes: Cognitive improvement is generally less predictable and less frequent than gait improvement.
• Prognostic Factors: Patients with a shorter duration of symptoms and those who show a dramatic response to the tap test have the highest likelihood of successful outcomes.

7. Frequently Asked Questions (FAQ)

1. Is NPH the same as "water on the brain"?
Technically, yes, but "water on the brain" usually refers to high-pressure hydrocephalus. NPH is distinct because the pressure is normal, making it a chronic, physiological, and structural issue rather than an acute medical emergency.

2. Can NPH be cured with medication?
No. There are no pharmacological treatments for NPH. While some clinicians may try acetazolamide in specific, non-surgical candidates, it is not a standard or effective long-term treatment.

3. What is the success rate of a VP shunt?
Approximately 75% of properly selected patients experience significant improvement in their gait and quality of life.

4. Why is the gait called "magnetic"?
It refers to the patient’s difficulty in initiating steps and lifting their feet, creating the visual impression that their feet are physically magnetized to the floor.

5. How long does a shunt last?
Shunts are permanent implants. However, they may require revision if they become blocked, infected, or if the pressure settings need adjustment.

6. Does NPH cause memory loss?
Yes, but it is typically "subcortical" dementia. Patients struggle with planning, focus, and speed of thought rather than losing memory of specific past events.

7. Can a patient have NPH and Alzheimer’s simultaneously?
Yes. This is called "comorbid" disease. In these cases, the shunt may improve the gait, but the underlying cognitive impairment from Alzheimer’s will remain.

8. What is the Evans' Index?
It is a radiological measurement used to diagnose ventricular enlargement. It is calculated by dividing the maximum width of the frontal horns by the maximum internal diameter of the skull.

9. Is NPH hereditary?
No. Idiopathic NPH is generally considered a sporadic disease of aging, not a genetic or hereditary condition.

10. What is the role of an orthopedic specialist in NPH?
Orthopedists are often the first to see these patients because they present with falls, hip fractures, or chronic instability. Recognizing the "gait-first" presentation of NPH is essential for preventing secondary orthopedic injuries.

8. Conclusion for Clinical Practice

Normal Pressure Hydrocephalus is a critical diagnosis in the geriatric population. Because it presents with symptoms that are frequently dismissed as "normal aging," clinical vigilance is required. A multidisciplinary approach—involving neurologists, neurosurgeons, and orthopedic specialists—is essential for accurate diagnosis and successful surgical intervention. By identifying these patients early, we can prevent years of decline and significantly improve the patient's functional autonomy.

Disclaimer: This guide is intended for educational purposes for medical professionals and does not constitute individual medical advice. Always consult with a board-certified neurosurgeon for clinical cases involving potential hydrocephalus.